Pharmacodynamic Models for Agents that Alter Production of Natural Cells with Various Distributions of Lifespans

Indirect pharmacodynamic response (IDR) models were developed for agents which alter the generation of cell populations with arbitrary lifespan distributions. These models extend lifespan based IDR models introduced previously [J. Pharmacokinet. Biopharm. 27: 467, 1999] for cell populations with the same lifespan (“delta” distribution). Considered are cell populations exhibiting time-invariant lifespan distributions described by the probability density function ℓ(τ). It is assumed that cell response (R) is produced at a zero-order rate (kin(t)) and is eliminated from the population when the cell lifespan expires. The cell loss rate is calculated as kin*ℓ(t), where ‘*’ denotes the convolution operator. Therapeutic agents can stimulate or inhibit production rates according to the Hill function: 1 ± H(C(t)) where H(C(t)) contains the capacity (Smax) and potency (SC50) parameters and C(t) is a pharmacokinetic function. The production rate is kin(t)=kin· [ 1±H(C(t))]. The operational model is dR/dt = kin(t)−kin*ℓ(t) with the baseline condition R0 = kin· TR, where TR is the mean lifespan. Single populations as well as populations with precursors were examined by simulation to establish the role of lifespan distribution parameters (mean and standard deviation) in controlling the response vs. time profile. Estimability of parameters was assessed. Numerical techniques of solving differential equations with the convolution integral were proposed. In addition, the models were applied to literature data to describe the stimulatory effects of single doses of recombinant human erythropoietin on reticulocytes in blood. The estimates of Smax and SC50 for these agents were obtained along with means and standard deviations for reticulocyte lifespan distributions. The proposed models can be used to analyze the pharmacodynamics of agents which alter natural cell production yielding parameters describing their efficacy and potency as well as means and standard deviations for cell lifespan distributions.

[1]  H. Cramér Mathematical methods of statistics , 1947 .

[2]  E. Murphy,et al.  The estimation of blood platelet survival. I. General principles of the study of cell survival. , 1969, Thrombosis et diathesis haemorrhagica.

[3]  L. Sheiner,et al.  A pharmacodynamic model of erythropoietin therapy for uremic anemia , 1992, Clinical pharmacology and therapeutics.

[4]  H. Warnke,et al.  Kinetics of reticulocyte maturity fractions and indices and iron status during therapy with epoetin beta (recombinant human erythropoietin) in cardiac surgery patients , 1997, American journal of hematology.

[5]  Lewis B. Sheiner,et al.  Some suggestions for measuring predictive performance , 1981, Journal of Pharmacokinetics and Biopharmaceutics.

[6]  Assessment of Dosing Impact on Intra-Individual Variability in Estimation of Parameters for Basic Indirect Response Models , 2006, Journal of Pharmacokinetics and Pharmacodynamics.

[7]  W J Jusko,et al.  Transit compartments versus gamma distribution function to model signal transduction processes in pharmacodynamics. , 1998, Journal of pharmaceutical sciences.

[8]  M. Karlsson,et al.  Semiphysiological model for the time course of leukocytes after varying schedules of 5-fluorouracil in rats. , 2000, The Journal of pharmacology and experimental therapeutics.

[9]  A Schumitzky,et al.  A program package for simulation and parameter estimation in pharmacokinetic systems. , 1979, Computer programs in biomedicine.

[10]  A. Dornhorst The interpretation of red cell survival curves. , 1951, Blood.

[11]  M Kimmel,et al.  Non‐parametric analysis of platelet lifespan , 1990, Cell and tissue kinetics.

[12]  Dornhorst Ac The interpretation of red cell survival curves. , 1951 .

[13]  L. Harker,et al.  Effects of megakaryocyte growth and development factor on platelet production, platelet life span, and platelet function in healthy human volunteers , 2000 .

[14]  H. Akaike A new look at the statistical model identification , 1974 .

[15]  R. Ramakrishnan,et al.  Basic Pharmacodynamic Models for Agents That Alter Production of Natural Cells , 1999, Journal of Pharmacokinetics and Biopharmaceutics.

[16]  W. Cheung,et al.  Pharmacokinetics and pharmacodynamics of recombinant human erythropoietin after single and multiple subcutaneous doses to healthy subjects* , 1998, Clinical pharmacology and therapeutics.

[17]  R. Aster,et al.  Platelet Kinetics: radioisotopic, cytological, mathematical and clinical aspects , 1972 .

[18]  R. Ramakrishnan,et al.  Pharmacokinetic and Pharmacodynamic Modeling of Recombinant Human Erythropoietin After Single and Multiple Doses in Healthy Volunteers , 2004, Journal of clinical pharmacology.

[19]  M. Mackey,et al.  Age-structured and two-delay models for erythropoiesis. , 1995, Mathematical biosciences.

[20]  P. Bergner On the stochastic interpretation of cell survival curves , 1962 .

[21]  Varun Garg,et al.  Comparison of four basic models of indirect pharmacodynamic responses , 1993, Journal of Pharmacokinetics and Biopharmaceutics.

[22]  Peter Veng Pedersen,et al.  Curve fitting and modeling in pharmacokinetics and some practical experiences with NONLIN and a new program FUNFIT , 1977, Journal of Pharmacokinetics and Biopharmaceutics.

[23]  Murphy Ea,et al.  The estimation of blood platelet survival. I. General principles of the study of cell survival. , 1969 .

[24]  L. Harker,et al.  Effects of megakaryocyte growth and development factor on platelet production, platelet life span, and platelet function in healthy human volunteers. , 2000, Blood.

[25]  P. Berk,et al.  Chapter 24 – The Biological Life of the Red Cell* , 1975 .

[26]  B. Ridell,et al.  On the analysis of platelet survival curves and the calculation of platelet production and destruction. , 2009, Scandinavian journal of haematology.

[27]  F. Stohlman,et al.  The kinetics of cellular proliferation , 1961 .

[28]  A. M'Kendrick Applications of Mathematics to Medical Problems , 1925, Proceedings of the Edinburgh Mathematical Society.

[29]  J. Widness,et al.  An Integrated Pharmacodynamic Analysis of Erythropoietin, Reticulocyte, and Hemoglobin Responses in Acute Anemia , 2002, Pharmaceutical Research.

[30]  E. Murphy,et al.  The Estimation of Blood Platelet Survival II. The Multiple Hit Model , 1971, Thrombosis and Haemostasis.

[31]  W. Jusko,et al.  Population Cell Life Span Models for Effects of Drugs Following Indirect Mechanisms of Action , 2005, Journal of Pharmacokinetics and Pharmacodynamics.

[32]  Kendrick,et al.  Applications of Mathematics to Medical Problems , 1925, Proceedings of the Edinburgh Mathematical Society.

[33]  W. Jusko,et al.  Pharmacokinetic and pharmacodynamic modeling of recombinant human erythropoietin after multiple subcutaneous doses in healthy subjects. , 2005, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[34]  Douglas MacN. Surgenor,et al.  The red blood cell , 1974 .